Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781372 | 0.91 | NOTUM (0.42) | NOTUMKEAP1RIPK2CHEK1CYP19A1 | |
| SCHEMBL29538864 | 0.91 | NOTUM (0.42) | NOTUMKEAP1RIPK2CHEK1CYP19A1 | |
| SCHEMBL29933995 | 0.85 | CYP2A6 (0.36) | RIPK2HCRTR1HCRTR2SCN10A | |
| SCHEMBL16419692 | 0.85 | CYP2A6 (0.36) | RIPK2HCRTR1HCRTR2SCN10A | |
| SCHEMBL16419697 | 0.76 | NOTUM (0.46) | NOTUMKEAP1CHEK1CYP19A1 | |
| SCHEMBL29800355 | 0.75 | NOTUM (0.53) | NOTUMKEAP1CHEK1CYP19A1 | |
| SCHEMBL17819625 | 0.73 | KDM4E (0.44) | NOTUMRIPK2 | |
| SCHEMBL31157076 | 0.71 | NOTUM (0.46) | NOTUMKEAP1CHEK1CYP19A1 | |
| SCHEMBL4540648 | 0.70 | NOTUM (0.58) | NOTUMKEAP1HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16419708 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159814-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159814-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | NOTUM 2448/4885KEAP1 804/4885RIPK2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.